JP2023182691A5 - - Google Patents
Info
- Publication number
- JP2023182691A5 JP2023182691A5 JP2023169177A JP2023169177A JP2023182691A5 JP 2023182691 A5 JP2023182691 A5 JP 2023182691A5 JP 2023169177 A JP2023169177 A JP 2023169177A JP 2023169177 A JP2023169177 A JP 2023169177A JP 2023182691 A5 JP2023182691 A5 JP 2023182691A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548632P | 2017-08-22 | 2017-08-22 | |
| US62/548,632 | 2017-08-22 | ||
| JP2020511375A JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| PCT/US2018/047286 WO2019040471A1 (en) | 2017-08-22 | 2018-08-21 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511375A Division JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023182691A JP2023182691A (ja) | 2023-12-26 |
| JP2023182691A5 true JP2023182691A5 (cg-RX-API-DMAC10.html) | 2026-01-29 |
Family
ID=63638351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511375A Active JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| JP2023169177A Pending JP2023182691A (ja) | 2017-08-22 | 2023-09-29 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511375A Active JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12139546B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3672620A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7781519B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3071387A1 (cg-RX-API-DMAC10.html) |
| MX (2) | MX2020002057A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019040471A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210642A1 (en) | 2019-04-10 | 2020-10-15 | Camp4 Therapeutics Corporation | Methods and compositions for treating urea cycle disorders |
| EP4262781A4 (en) * | 2020-12-16 | 2025-02-12 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| WO2023122762A1 (en) * | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836308B2 (ja) | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | 抗体の製造方法 |
| US4206199A (en) | 1977-07-22 | 1980-06-03 | Takeda Chemical Industries, Ltd. | Novel glucagon fragment and its derivatives |
| JPS56163456A (en) | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| US4423034A (en) | 1980-10-16 | 1983-12-27 | Toyo Jozo Kabushiki Kaisha | Process for the preparation of antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3515112B2 (ja) | 1992-08-28 | 2004-04-05 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン・レセプタ |
| JP2729159B2 (ja) | 1994-10-31 | 1998-03-18 | 日清製粉株式会社 | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7301036B2 (en) | 2003-12-19 | 2007-11-27 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
| SI1756064T1 (sl) | 2004-06-04 | 2008-12-31 | Merck & Co Inc | Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| DE602005017895D1 (de) | 2004-07-07 | 2010-01-07 | Merck & Co Inc | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren |
| AU2005269792B9 (en) | 2004-07-22 | 2008-11-27 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| US8084489B2 (en) | 2005-02-11 | 2011-12-27 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| US8318760B2 (en) | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
| CN101146763A (zh) | 2005-03-30 | 2008-03-19 | 默克公司 | 胰高血糖素受体拮抗剂化合物、含有这种化合物的组合物以及使用方法 |
| AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| AU2007240315A1 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | GLP-1 compound/glucagon antibody compositions |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| MX2009008534A (es) | 2007-02-09 | 2009-11-23 | Metabasis Therapeutics Inc | Antagonistas novedosos del receptor de glucagon. |
| AR070844A1 (es) | 2008-03-27 | 2010-05-05 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2 |
| US8623818B2 (en) | 2008-05-16 | 2014-01-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonists, compositions, and methods for their use |
| US8436015B2 (en) | 2008-09-15 | 2013-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010071750A1 (en) | 2008-12-19 | 2010-06-24 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
| US20110281795A1 (en) | 2009-01-28 | 2011-11-17 | Songnian Lin | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010093535A1 (en) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8809579B2 (en) | 2009-02-13 | 2014-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩 |
| FR2959129B1 (fr) * | 2010-04-21 | 2013-02-01 | Lucane Pharma | Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| EP3263102A1 (en) | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| JP2015505828A (ja) | 2011-12-02 | 2015-02-26 | イーライ リリー アンド カンパニー | 抗グルカゴン抗体およびその使用 |
| EP3194441A1 (en) | 2014-09-16 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
-
2018
- 2018-08-21 US US16/640,907 patent/US12139546B2/en active Active
- 2018-08-21 JP JP2020511375A patent/JP7781519B2/ja active Active
- 2018-08-21 EP EP18772997.5A patent/EP3672620A1/en active Pending
- 2018-08-21 CA CA3071387A patent/CA3071387A1/en active Pending
- 2018-08-21 MX MX2020002057A patent/MX2020002057A/es unknown
- 2018-08-21 WO PCT/US2018/047286 patent/WO2019040471A1/en not_active Ceased
-
2020
- 2020-02-21 MX MX2024011106A patent/MX2024011106A/es unknown
-
2023
- 2023-09-29 JP JP2023169177A patent/JP2023182691A/ja active Pending
-
2024
- 2024-10-03 US US18/906,101 patent/US20250101119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114616249B (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| JP2024016177A5 (cg-RX-API-DMAC10.html) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| KR102039198B1 (ko) | 악액질 치료법 | |
| JP7266108B2 (ja) | 治療用抗体製剤 | |
| JP2024531151A5 (cg-RX-API-DMAC10.html) | ||
| JP7398958B2 (ja) | 安定的抗ｏｓｍｒ抗体製剤 | |
| CN114762678B (zh) | 抗tigit抗体药物组合物及其用途 | |
| TWI860741B (zh) | Pvrig/tigit雙特異性抗體藥物組合物及其用途 | |
| AU2024202601A1 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| JP2020531532A5 (cg-RX-API-DMAC10.html) | ||
| HRP20160302T1 (hr) | Monoklonska protutijela protiv feroportina 1 i njihova upotreba | |
| CN117159703A (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| JP7781519B2 (ja) | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 | |
| CN119677508A (zh) | 与抗因子xi/因子xia抗体的组合疗法 | |
| US20190322734A1 (en) | Treatment paradigm | |
| JP2021533142A5 (cg-RX-API-DMAC10.html) | ||
| KR20250079929A (ko) | 항-FcRN 항체를 이용한 그레이브스병의 치료 방법 | |
| KR20250011948A (ko) | 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법 | |
| US20240238272A1 (en) | Treatment of antiphospholipid syndrome using s-hydroxychloroquine | |
| US20250340643A1 (en) | Anti-CTLA Antibody Compositions and Related Methods | |
| RU2025126086A (ru) | Композиции, содержащие биспецифическое антитело к gprc5d/cd3 | |
| RU2025129547A (ru) | Способы применения мультиспецифических связывающих белков | |
| HK40102408B (en) | Pharmaceutical composition containing anti-lag-3 antibody and application thereof | |
| HK40102408A (en) | Pharmaceutical composition containing anti-lag-3 antibody and application thereof |